<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd" xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>00000cmm a22000004i 4500</leader>
  <controlfield tag="001">UP-99796217611094602</controlfield>
  <controlfield tag="003">Buklod</controlfield>
  <controlfield tag="005">20140127112436.0</controlfield>
  <controlfield tag="006">m    go  j        </controlfield>
  <controlfield tag="007">cr |n |||auu|a</controlfield>
  <controlfield tag="008">100922s2011    nyu        u        eng d</controlfield>
  <datafield tag="020" ind1=" " ind2=" ">
   <subfield code="a">9781441974495 (eBook)</subfield>
  </datafield>
  <datafield tag="020" ind1=" " ind2=" ">
   <subfield code="a">1441974490 (eBook)</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(iLib)UPD-00212403850</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
   <subfield code="a">DLC</subfield>
   <subfield code="d">DML</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
   <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="042" ind1=" " ind2=" ">
   <subfield code="a">DMLUC</subfield>
  </datafield>
  <datafield tag="084" ind1=" " ind2=" ">
   <subfield code="a">RS 189</subfield>
   <subfield code="b">G33 2011eb</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Gad, Shayne C.</subfield>
   <subfield code="c">1948-</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Safety evaluation of pharmaceuticals and medical devices</subfield>
   <subfield code="h">[electronic resource]</subfield>
   <subfield code="b">international regulatory guidelines</subfield>
   <subfield code="c">Shayne C. Gad.</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
   <subfield code="a">New York</subfield>
   <subfield code="b">Springer</subfield>
   <subfield code="c">c2011.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
   <subfield code="a">1 online resource (xi, 126 p.)</subfield>
   <subfield code="b">ill. (some col.)</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2=" ">
   <subfield code="a">Preface -- Introduction to Safety Assessment in Drug and Medical Device Development -- Drugs: The General Case -- Ind Enabling Toxicology Programs -- Nonclinical Safety Evaluation Studies Conducted To Support Continued Clinical Development -- Supporting Marketing Applications -- Special Therapeutic Category And Route Of Administration Cases -- Device Safety Evaluation -- Appendix A -- Index.</subfield>
  </datafield>
  <datafield tag="506" ind1=" " ind2=" ">
   <subfield code="a">IP-based subscription, access limited to within on-campus computer network.</subfield>
   <subfield code="c">Access via Electronic Resources of the UPD University Library Website.</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
   <subfield code="a">Safety Evaluation of Pharmaceuticals and Medical Devices has been written to provide complete, ready and clear guidance as to what nonclinical safety assessment tests need to be performed to move a regulated therapeutic medical product into and through the development process and to marketing approval. This intent is purposely extended to cover the closely related product types of vaccines, biotechnology products, gene therapy, cell therapy, and combination products into a single, concise guide for the process in all the major world market countries. The approach of this volume is to first address the broadest scope ?general case? for the regulatory nonclinical safety evaluation by ICH and ISO adhering countries, then to branch out to cover the differences in requirements associated with specific therapeutic areas (such as oncology), major routes of administration (with oral being the general case, other routes starting with parentheral, dermal and inhalation are addressed). Large molecules biotechnology products are then considered, followed by special courses of product marketing approval, and finally the remaining national differences.</subfield>
  </datafield>
  <datafield tag="533" ind1=" " ind2=" ">
   <subfield code="a">Electronic reproduction.</subfield>
   <subfield code="b">New York</subfield>
   <subfield code="c">SpringerLink</subfield>
   <subfield code="d">2011.</subfield>
   <subfield code="n">Available via World Wide Web through Springerlink.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
   <subfield code="a">Drugs</subfield>
   <subfield code="x">Standards.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
   <subfield code="a">Medical instruments and apparatus</subfield>
   <subfield code="x">Safety regulations.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
   <subfield code="a">Electronic books.</subfield>
  </datafield>
  <datafield tag="710" ind1="2" ind2=" ">
   <subfield code="a">SpringerLink (Online service).</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="z">Available for University of the Philippines Diliman via SpringerLink. Click here to access</subfield>
   <subfield code="u">http://link.springer.com/book/10.1007/978-1-4419-7449-5</subfield>
  </datafield>
  <datafield tag="856" ind1=" " ind2=" ">
   <subfield code="a">(viewed 19 May 2014)</subfield>
  </datafield>
  <datafield tag="905" ind1=" " ind2=" ">
   <subfield code="a">FO</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="a">Monograph</subfield>
  </datafield>
  <datafield tag="852" ind1="0" ind2=" ">
   <subfield code="a">UPD</subfield>
   <subfield code="b">DMLR</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
   <subfield code="a">Electronic Resource</subfield>
  </datafield>
 </record>
</collection>
